Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC).
We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival.
Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85–49.30) in CCRT group and 13.29 weeks (95 % CI 10.42–16.15) in BSC group (P < 0.001). Nausea and anemia were the most common toxicities observed.
Patients with locally advanced BTC who were treated with 5-FU-based or GEM-based CCRT seem to have a better survival than those who received BSC. The treatment-related toxicity was mild. GEM-based or 5-FU-based CCRT showed similar survival advantages.
- Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer
Cancer Chemotherapy and Pharmacology
Volume 73, Issue 1 , pp 191-198
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Biliary tract cancer
- Concurrent chemoradiation
- GB cancer
- Locally advanced
- Industry Sectors
- Author Affiliations
- 1. Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea
- 2. Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea
- 3. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea
- 4. Department of Diagnostic Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea
- 5. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea